(Q42992104)

12 November 2017

title

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus (English)

1 reference

12 November 2017

1 reference

2

1 reference

12 November 2017

7

1 reference

12 November 2017

10

1 reference

12 November 2017

Ignacio Melero, MD-PhD

series ordinal

9

object named as

Ignacio Melero

1 reference

12 November 2017

Francisco Borrás-Cuesta

series ordinal

5

object named as

Francisco Borrás-Cuesta

1 reference

12 November 2017

1

Laura Arribillaga

1 reference

12 November 2017

4

Marta Gorraiz

1 reference

12 November 2017

3

Ainhoa Arina

1 reference

12 November 2017

Juan Ruiz

6

1 reference

12 November 2017

Lieping Chen

series ordinal

8

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 November 2017

1 reference

12 November 2017

volume

23

1 reference

12 November 2017

issue

27

1 reference

12 November 2017

page(s)

3493-3499

1 reference

T-lymphocyte response to hepatitis C virus in different clinical courses of infection

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Determinants of viral clearance and persistence during acute hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Role of the specific T-cell response for clearance and control of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Dendritic cells and the control of immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Selective induction of high avidity CTL by altering the balance of signals from APC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

4-1 BB ligand--just another costimulating molecule?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Cutting edge: Expression of functional CD137 receptor by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

4-1BB T-cell antigen binds to mature B cells and macrophages, and costimulates anti-mu-primed splenic B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

In Vivo Triggering Through 4-1BB Enables Th-Independent Priming of CTL in the Presence of an Intact CD28 Costimulatory Pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Costimulation of human CD28- T cells by 4-1BB ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Insights on the amino acid side-chain interactions of a synthetic T-cell determinant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Viral mutations, TCR antagonism and escape from the immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent Viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Ligation of 4-1BB (CDw137) regulates graft-versus-host disease, graft-versus-leukemia, and graft rejection in allogeneic bone marrow transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

Constitutive expression of 4-1BB on T cells enhances CD4+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.02.003

10.1016/J.VACCINE.2005.02.003

7 January 2021

Identifiers

DOI

1 reference

12 November 2017

1 reference